由Cofilin1介导的细胞骨架重构可调控泛癌症CD8+ T细胞免疫疗法的疗效
Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses
Le Li, Zheng Chao, Junbo Li, Chao Ma, Ren Zhang, Jie Zhang, Jing Luo, David Horne, Yanan Wang, Xiaodong Hao, Chunyu Zhang, Xiangdong Guo, Sheng Ma, Hao Peng, Zhiquan Hu, Bertram Yuh, Gong-Hong Wei, X
Journal:Cell Reports Medicine
IF:14
DOI:10.1016/j.xcrm.2026.102984
PMID:42586064
Published:2026-08-12
research field:
Abstract
Tumor immunotherapies enhance CD8 + T cell function, yet heterogeneous responses in “cold” and “hot” tumors remain a challenge. Although biomechanical cues modulate T cell cytotoxicity, strategies to harness these forces for broad antitumor potentiation remain elusive. Here, integrating pan-cancer single-cell RNA sequencing data, we identify cofilin 1 (CFL1) as a determinant of immunotherapy response. CFL1 overexpression synergizes with CD8 + T cell-targeted immunotherapy across tumor types, driving intratumoral T cell expansion while rendering tumors physically vulnerable. Mechanistically, CFL1 hyperactivation induces F-actin bundling and actin rod accumulation, elevating cytoskeletal tension to facilitate immunological synapse formation. Conversely, CFL1 inactivation through phosphorylation or our newly identified lactylation correlates with poor outcomes. Combination therapy using adeno-associated virus delivering constitutively active CFL1 and PD-1 blockade achieves near-complete tumor eradication. Together, our findings position CFL1 as a biomechanical checkpoint governing tumor vulnerability to CD8 + T cells through immunological synapse licensing, offering a strategy to overcome immunotherapy resistance.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


